AU2006270162B2 - A powder mix of potassium calcium citrate for the treatment of kidney stones and osteoporosis - Google Patents

A powder mix of potassium calcium citrate for the treatment of kidney stones and osteoporosis Download PDF

Info

Publication number
AU2006270162B2
AU2006270162B2 AU2006270162A AU2006270162A AU2006270162B2 AU 2006270162 B2 AU2006270162 B2 AU 2006270162B2 AU 2006270162 A AU2006270162 A AU 2006270162A AU 2006270162 A AU2006270162 A AU 2006270162A AU 2006270162 B2 AU2006270162 B2 AU 2006270162B2
Authority
AU
Australia
Prior art keywords
citrate
calcium
meq
potassium
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2006270162A
Other languages
English (en)
Other versions
AU2006270162A1 (en
Inventor
Charles Y. C. Pak
Khashayar Sakhaee
Neill B. Walsdorf
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Texas System
Original Assignee
University of Texas System
University of Texas at Austin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Texas System, University of Texas at Austin filed Critical University of Texas System
Publication of AU2006270162A1 publication Critical patent/AU2006270162A1/en
Assigned to THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM reassignment THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM Request for Assignment Assignors: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM, MISSION PHARMACAL CO.
Application granted granted Critical
Publication of AU2006270162B2 publication Critical patent/AU2006270162B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A61K33/08—Oxides; Hydroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A61K33/10—Carbonates; Bicarbonates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
AU2006270162A 2005-07-15 2006-07-13 A powder mix of potassium calcium citrate for the treatment of kidney stones and osteoporosis Ceased AU2006270162B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11/183,140 2005-07-15
US11/183,140 US20070077314A1 (en) 2005-07-15 2005-07-15 Powder mix of potassium calcium citrate for the treatment of kidney stones and osteoporosis
PCT/US2006/027398 WO2007011740A2 (en) 2005-07-15 2006-07-13 A powder mix of potassium calcium citrate for the treatment of kidney stones and osteoporosis

Publications (2)

Publication Number Publication Date
AU2006270162A1 AU2006270162A1 (en) 2007-01-25
AU2006270162B2 true AU2006270162B2 (en) 2012-01-12

Family

ID=37669400

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2006270162A Ceased AU2006270162B2 (en) 2005-07-15 2006-07-13 A powder mix of potassium calcium citrate for the treatment of kidney stones and osteoporosis

Country Status (5)

Country Link
US (2) US20070077314A1 (cg-RX-API-DMAC7.html)
EP (1) EP1922064A4 (cg-RX-API-DMAC7.html)
JP (1) JP2009514786A (cg-RX-API-DMAC7.html)
AU (1) AU2006270162B2 (cg-RX-API-DMAC7.html)
WO (1) WO2007011740A2 (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112015023495A8 (pt) 2013-03-15 2019-12-03 Massachusetts Gen Hospital bebida compreendendo citrato, kit, e, concentrado de bebida
US9529465B2 (en) 2013-12-02 2016-12-27 At&T Intellectual Property I, L.P. Secure interaction with input devices
WO2015120272A1 (en) * 2014-02-06 2015-08-13 University Of Houston System Organic acids as growth inhibitors of pathological calcification and uses thereof
US10285961B2 (en) 2014-02-06 2019-05-14 University Of Houston System Organic acids as agents to dissolve calcium minerals in pathological calcification and uses thereof
CN104069125B (zh) * 2014-07-16 2017-02-08 华南理工大学 一种用于泌尿系磷酸盐结石的溶石剂及其制备方法
WO2016159897A1 (en) * 2015-04-01 2016-10-06 Ay Doğan Potassium citrate suspension
WO2019035989A1 (en) * 2017-08-17 2019-02-21 The Board Of Regents Of The University Of Texas System PREVENTION OF CALCIUM OXALATE RENAL CALCULATIONS BY POTASSIUM HYDROXYCITRATE
IT202200021258A1 (it) * 2022-10-14 2024-04-14 Neilos S R L “Composizione nutraceutica o farmaceutica per il benessere renale”

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001005250A1 (en) * 1999-07-19 2001-01-25 Mission Pharmacal Company Potassium calcium citrate compositions and methods for production
US20020102331A1 (en) * 2000-10-16 2002-08-01 Chang Pei K. Calcium-supplemented beverages and method of making same
US6599544B2 (en) * 2000-01-26 2003-07-29 American Micronutrients, Inc. Calcium enrichment composition and method for producing the same
US20040009280A1 (en) * 2002-07-08 2004-01-15 Valencia Donna L. Powdered beverage mix with rapidly dissolving calcium
US20040101597A1 (en) * 2002-11-22 2004-05-27 Calapini Sarah A. Calcium fortified acidic beverages

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4888182A (en) * 1983-04-11 1989-12-19 Board Of Regents Of The University Of Texas System Compositions and methods of treating calcium renal stones
US4772467A (en) * 1985-02-19 1988-09-20 Board Of Regents, U T Systems Osteoporosis inhibition by dietary calcium supplementation
US4722847A (en) * 1986-05-07 1988-02-02 The Procter & Gamble Company Fruit juice beverages and juice concentrates nutritionally supplemented with calcium
US4871554A (en) * 1987-08-12 1989-10-03 Coca-Cola Company Calcium fortified food product
US5128374A (en) * 1987-08-28 1992-07-07 The Procter & Gamble Company Use of calcium citrate malate for the treatment of osteoporosis and related disorders
ES2061394B1 (es) * 1993-02-05 1995-06-16 Robert S A Lab Procedimiento de fabricacion de un granulado de citrato potasico con cesion retardada.
US6680305B1 (en) * 1993-06-04 2004-01-20 Biotime, Inc. Physiologically acceptable aqueous solutions and methods for their use
DE19503190A1 (de) * 1995-02-01 1996-08-08 Dietl Hans Mittel zur Beeinflussung von Störungen der Knochenbildung
GB9603518D0 (en) * 1996-02-20 1996-04-17 Smithkline Beecham Plc Novel process
US20030175360A1 (en) * 2002-02-22 2003-09-18 Renzo Luzzatti Symptomatic relief of gastrointestinal disorders
US7507421B2 (en) * 2002-04-30 2009-03-24 Unibar Corporation Hydroxycitric acid salt composition and method of making
US20040185119A1 (en) * 2003-02-26 2004-09-23 Theuer Richard C. Method and compositions for treating gastric hyperacidity while diminishing the likelihood of producing vitamin deficiency

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001005250A1 (en) * 1999-07-19 2001-01-25 Mission Pharmacal Company Potassium calcium citrate compositions and methods for production
US6599544B2 (en) * 2000-01-26 2003-07-29 American Micronutrients, Inc. Calcium enrichment composition and method for producing the same
US20020102331A1 (en) * 2000-10-16 2002-08-01 Chang Pei K. Calcium-supplemented beverages and method of making same
US7052725B2 (en) * 2000-10-16 2006-05-30 Pepsico, Inc. Calcium-supplemented beverages and method of making same
US20040009280A1 (en) * 2002-07-08 2004-01-15 Valencia Donna L. Powdered beverage mix with rapidly dissolving calcium
US20040101597A1 (en) * 2002-11-22 2004-05-27 Calapini Sarah A. Calcium fortified acidic beverages

Also Published As

Publication number Publication date
AU2006270162A1 (en) 2007-01-25
US20070077314A1 (en) 2007-04-05
WO2007011740A3 (en) 2009-04-30
US20100227006A1 (en) 2010-09-09
EP1922064A4 (en) 2010-12-22
US8216614B2 (en) 2012-07-10
EP1922064A2 (en) 2008-05-21
JP2009514786A (ja) 2009-04-09
WO2007011740A2 (en) 2007-01-25

Similar Documents

Publication Publication Date Title
US8216614B2 (en) Powder mix of potassium calcium citrate for the treatment of kidney stones and osteoporosis
AU2008216234B2 (en) Improved stability in vitamin and mineral supplements
DK169231B1 (da) Calciumkosttilskudspræparat til opløsning i vand, fremgangsmåde til fremstilling af et sådant, fremgangsmåde til fremstilling af en drikkelig væske baseret derpå, og drikkelig væske, der er egnet som kosttilskud af calcium
US8759398B2 (en) Phosphorus binder composition for treatment of hyperphosphatemia
CA2587924C (en) Oral compositions for absorption of phosphorus compounds
KR20110128329A (ko) 인산염 흡착제
NO342559B1 (no) Farmasøytisk formulering omfattende lantankarbonat og anvendelse av denne
US8129430B2 (en) Method of reducing phosphate nephropathy in a mammal
US20130189377A1 (en) Compositions
US6287607B2 (en) Potassium calcium citrate compositions and methods therefor
JPS62501846A (ja) 液体食事カルシウム補足
WO2007108712A1 (en) Kit and method for treating or preventing anemia caused by iron deficiency
WO2019201707A1 (de) Stoffgemisch umfassend k-mg-citrat zur verwendung als arzneimittel
RU2527042C1 (ru) Биологически активная добавка к пище для профилактики заболеваний остеопорозом
AU2018327614B2 (en) Composition for calcium supplementation
RU2796676C1 (ru) Водорастворимые таблетки колекальциферола и способ их получения
US12251400B2 (en) Liquid concentrates of calcium and magnesium
KR100312045B1 (ko) 골다공증의 치료를 위한 방법및 조합물
US20110269837A1 (en) Phosphorus binder composition for treatment of hyperphosphatemia
US20200078395A1 (en) Averting complications of pump inhibitor therapy by effervescent calcium magnesium citrate
JP3486755B2 (ja) 高燐血症予防・治療剤
Abrahams et al. Urinary Stone Inhibitors: Citrate and Magnesium
CN102232964A (zh) 治疗泌尿系统结石及高尿酸血症的药
SHLAFER et al. 27 Drug therapy and nutrition

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SY

Free format text: FORMER APPLICANT(S): BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM; MISSION PHARMACAL CO.

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired